Related Experiment Video
Updated: May 22, 2026
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia
Nicholas C Wong1, David Ashley, Zac Chatterton
1Murdoch Childrens Research Institute, Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia.
Insights
Aberrant DNA methylation is common in childhood acute lymphoblastic leukemia (ALL), a leading cause of childhood cancer mortality. This study identified specific DNA methylation markers unique to ALL at diagnosis, offering potential targets for new epigenetic therapies.
Area of Science:
- Oncology
- Epigenetics
- Pediatric Hematology
Background:
- Childhood acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and a significant cause of mortality.
- The underlying mechanisms driving the development of childhood ALL are not fully understood.
- Aberrant DNA methylation is increasingly recognized as a key epigenetic mechanism in cancer development.
Purpose of the Study:
- To investigate the role of recurrent aberrant DNA methylation in the pathogenesis of childhood pre-B cell acute lymphoblastic leukemia (ALL).
- To define a genome-scale DNA methylation profile specific to the ETV6-RUNX1 subtype of pediatric ALL.
- To identify novel DNA methylation markers for diagnostic and therapeutic targeting in ALL.
Main Methods:
- Genome-scale DNA methylation profiling was performed on archival bone marrow samples from pediatric ALL patients at diagnosis and remission.
- A disease-specific DNA methylation signature was derived and validated in independent patient cohorts.
- Analysis included comparison with healthy CD34+ cells and assessment across different cytogenetic subtypes.
Main Results:
- A unique DNA methylation signature was identified at diagnosis, distinct from remission samples.
- Fifteen specific DNA methylation loci were sufficient to differentiate ALL from disease-free states.
- These aberrant DNA methylation patterns were recurrent across various cytogenetic subtypes of pre-B cell ALL, indicating a shared disease pathway.
Conclusions:
- Recurrent aberrant genomic methylation is a common hallmark of pre-B cell ALL, suggesting a unified mechanism in disease initiation.
- The identified DNA methylation signature provides novel biomarkers for ALL detection.
- These findings highlight potential targets for the development of innovative epigenetic-based therapies for childhood ALL.
Abstract:
Pre-B cell acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy and remains one of the highest causes of childhood mortality. Despite this, the mechanisms leading to disease remain poorly understood. We asked if recurrent aberrant DNA methylation plays a role in childhood ALL and have defined a genome-scale DNA methylation profile associated with the ETV6-RUNX1 subtype of pediatric ALL. Archival bone marrow smears from 19 children collected at diagnosis and remission were used to derive a disease specific DNA methylation profile. The gene signature was confirmed in an independent cohort of 86 patients. A further 163 patients were analyzed for DNA methylation of a three gene signature. We found that the DNA methylation signature at diagnosis was unique from remission. Fifteen loci were sufficient to discriminate leukemia from disease-free samples and purified CD34+ cells. DNA methylation of these loci was recurrent irrespective of cytogenetic subtype of pre-B cell ALL. We show that recurrent aberrant genomic methylation is a common feature of pre-B ALL, suggesting a shared pathway for disease development. By revealing new DNA methylation markers associated with disease, this study has identified putative targets for development of novel epigenetic-based therapies.
